Celcuity Inc. (NASDAQ:CELC) Short Interest Up 11.4% in September

Celcuity Inc. (NASDAQ:CELC) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 2,550,000 shares, a growth of 11.4% from the August 31st total of 2,290,000 shares. Based on an average daily volume of 416,400 shares, the days-to-cover ratio is presently 6.1 days.

Institutional Investors Weigh In On Celcuity

Several institutional investors have recently bought and sold shares of CELC. Point72 Asset Management L.P. purchased a new position in Celcuity during the 2nd quarter worth $951,000. Driehaus Capital Management LLC lifted its position in shares of Celcuity by 62.3% during the second quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company’s stock valued at $3,351,000 after purchasing an additional 78,525 shares in the last quarter. Blue Owl Capital Holdings LP purchased a new position in Celcuity during the second quarter worth about $1,065,000. Marshall Wace LLP grew its position in Celcuity by 40.0% in the 2nd quarter. Marshall Wace LLP now owns 152,291 shares of the company’s stock worth $2,495,000 after purchasing an additional 43,476 shares in the last quarter. Finally, Samlyn Capital LLC grew its holdings in shares of Celcuity by 92.4% in the second quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock valued at $21,735,000 after acquiring an additional 637,190 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Celcuity in a research note on Thursday, August 15th. Leerink Partners began coverage on shares of Celcuity in a research report on Monday, July 22nd. They set an “outperform” rating and a $29.00 price objective for the company. Lifesci Capital assumed coverage on shares of Celcuity in a research report on Monday, August 26th. They set an “outperform” rating and a $27.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Celcuity in a research note on Thursday, August 15th. Finally, Stifel Nicolaus decreased their price target on shares of Celcuity from $40.00 to $39.00 and set a “buy” rating for the company in a research note on Thursday, August 15th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $28.67.

Celcuity Stock Down 2.6 %

CELC traded down $0.39 during trading on Tuesday, hitting $14.52. 54,015 shares of the company’s stock were exchanged, compared to its average volume of 289,848. Celcuity has a fifty-two week low of $8.39 and a fifty-two week high of $22.19. The stock has a market cap of $509.67 million, a P/E ratio of -5.19 and a beta of 0.76. The business’s 50 day moving average is $16.27 and its two-hundred day moving average is $16.75. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.54.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.09. During the same quarter in the prior year, the firm posted ($0.66) earnings per share. As a group, equities analysts expect that Celcuity will post -2.54 earnings per share for the current fiscal year.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.